Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: Clinicopathological features, efficacy, and factors affecting survival

Basit Öğe Kaydı
dc.contributor.authorUlaş, Arife
dc.contributor.authorKöş, Tuğba
dc.contributor.authorAvcı, Nilüfer
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorBulut, Nilüfer
dc.contributor.authorDeğirmenci, Mustafa
dc.date.accessioned2020-04-30T13:33:04Z
dc.date.available2020-04-30T13:33:04Z
dc.date.issued2015
dc.departmentDÜ, Tıp Fakültesien_US
dc.descriptionPubMed ID: 25743846en_US
dc.description.abstractBackground: The aim of the present study was to evaluate clinicopathological characteristics of our early stage breast cancer patients who are epidermal growth factor receptor 2 (HER2) overexpressed/ amplified (HER2+), the efficacy of trastuzumab treatment and survival results. Materials and Methods: Patients with HER2- positive early stage breast cancer receiving adjuvant trastuzumab were investigated retrospectively. Clinicopathological features of 210 patients and treatment outcome were analysed. To evaluate survival rates, the Kaplan-Meier method was used. Univariate and multivariate analyses were conducted with the Cox regression model. Results: Mean age of the patients was 51.8, 71.9% being postmenopausal. Some 37.6% of patients were node negative, and 31% had T1 tumor size and 52.4% were positive for estrogen receptor. Of 210 patients, 89.5% completed planned 52 weeks adjuvant trastuzumab treatment. The median follow up was 27.5 months (6.0-86.0 ). Relapse free survival (RFS) was 68.0 months (95% CI: 62.1-74.0) and overall survival (OS) was 74.8 months (95% CI: 69.5-80.1). The 3 year OS for all patients was 92.0% and RFS was 79.6%. During follow up, relapse was detected at the rate of 14.3%. Trastuzumab associated cardiotoxicity was found at the rate of 3.3%. In univariate analyses, larger tumor size and grade III were significantly associated (p<0.05) with RFS. Multivariate analyses of covariates displaying p<0.05 identified grade III as an independent prognostic factor. Conclusions: In the present study, it was established that trastuzumab had a satisfactory safety profile and treatment efficacy as in other clinical studies and that among clinicopathological factors evaluated, only being grade 3 had a significant effect on RFS. The occurrence of relapse with adjuvant trastuzumab makes it necessary to identify molecular predictors, which will define this group better and help explain resistance to anti HER2 based therapies.en_US
dc.identifier.doi10.7314/APJCP.2015.16.4.1643en_US
dc.identifier.endpage1649en_US
dc.identifier.issn1513-7368
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1643en_US
dc.identifier.urihttps://dx.doi.org/10.7314/APJCP.2015.16.4.1643
dc.identifier.urihttps://hdl.handle.net/20.500.12684/534
dc.identifier.volume16en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdjuvant chemotherapy; Breast cancer; Grade III; HER2; Trastuzumaben_US
dc.titlePatients with HER2-positive early breast cancer receiving adjuvant trastuzumab: Clinicopathological features, efficacy, and factors affecting survivalen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
0534.pdf
Boyut:
380.56 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Öksüz Yayınlar Koleksiyonu